Attendee search 

Launchpad Venture Group, a Boston-based angel investment group, provides funding and advice to early-stage companies. Launchpad looks for innovative, technology-driven startup companies addressing a significant market opportunity where our investment can make a difference. We introduce entrepreneurs to potential investors through business plan presentations at monthly meetings. Launchpad Venture Group consists of individual angel investor members interested in achieving superior returns by financing privately held companies at an early stage of development.

Harnessing the brain’s immune system to fight neurodegeneration.

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.

CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.

engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNova’s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.

• No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart.

• VentriNova’s pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene – the key switch mediating heart cell division.

• VentriNova’s technology demonstrated in both small and large animals the ability to control the modulation (increased gene expression) of the cyclin A2 gene, therefore stimulating endogenous growth of new myocytes (heart muscle cells).

• VentriNova’s VN-100 technology is the conductor that orchestrates existing human heart
  cells to divide and regenerate themselves – a cellular function that is silenced in early human development.

Technology allows for a large quantity of active ingredient to be stored in a polymer matrix for a constant and slow targeted release. The active polymer is either embedded onto textile supports or on self adhesive multi layer long lasting patches or in particles in suspension in a solution. Products include pain relief devices (active textiles or patches), slimming devices, active foot care, mosquito control devices,...

We are able to have products lasting much longer because we can insert a large amount of actives in the device and we control the release kinetic. For instance, istead of having a 8 hour pain relief patch, we can obtain a reusable, washable patch equivalent lasting several weeks.

Rheumatology/ Orthopedics / Dermatology / Slimming / Parasite control

Long lasting active release / Constant release / Targeted area

Ampfuul's mission is to accelerate commercialization for our client's businesses in biotechnology and the life sciences by providing a suite of business development, marketing and sales services, including implementation of strategies.

More than 175 years ago, Albert Gallatin, the distinguished statesman who served as secretary of the treasury under Presidents Thomas Jefferson and James Madison, declared his intention to establish "in this immense and fast-growing city ... a system of rational and practical education fitting for all and graciously opened to all." Founded in 1831, New York University is now one of the largest private universities in the United States. Of the more than 3,000 colleges and universities in America, New York University is one of only 60 member institutions of the distinguished Association of American Universities

GeneDx specializes in genetic testing for rare hereditary disorders. Our mission is to make clinical testing available to people with rare genetic conditions and their families. Most of our tests include full gene analysis by DNA sequencing, the gold standard of genetic testing. We invite you to explore our site, where you will find comprehensive information and all of our paperwork. Please note that GeneDx does not provide Direct-to-Consumer testing. All tests must be ordered, and results sent to a health care provider, usually a physician or genetic counselor. Families are encouraged to present our material to their health care providers who can evaluate the appropriateness of testing. For diagnostic testing in rare disorders, contact GeneDx… Where rare is common.